larger trials are needed to further evaluate these investigational uses
The latter study also identified lysosomes as a major post-endocytic GLP-1R destination, raising the possibility that prolonged agonist exposure might result in GLP-1R degradation
Age, previous dieting history, and whether you regained weight after prior weight loss attempts also matter: people with a strong pattern of weight regain typically benefit from longer or indefinite maintenance therapy
Circulating succinate is associated with the elevation of blood pressure in SHR 92
Combining Wegovy with other weight loss medications has not been studied in clinical trials, raising concerns about unpredictable cardiovascular effects, worsened gastrointestinal side effects, and potential psychiatric or neurological risks
The weight loss drug frenzy took off when the FDA approved Novo Nordisk A/S's (NYSE:NVO) Wegvoy (semaglutide) in 2021